What is the recommended initial guideline‑directed medical therapy for a patient with heart failure with reduced ejection fraction who has no diabetes mellitus and no hypertension?

Initial GDMT for HFrEF Without Diabetes or Hypertension

For a patient with heart failure with reduced ejection fraction (HFrEF) who has no diabetes mellitus and no hypertension, initiate all four pillars of guideline-directed medical therapy simultaneously: an ACE inhibitor (or ARNI), a beta-blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor. 1

The Four-Pillar Approach

The 2022 AHA/ACC/HFSA guidelines establish that GDMT for HFrEF now consists of four medication classes, all with Class I recommendations 1. The absence of diabetes or hypertension does not alter this recommendation—these medications reduce mortality and hospitalization regardless of comorbidity status.

Start All Four Classes Early

• ACE inhibitor (or ARB if ACE-I intolerant): Start low dose, titrate to target

  • Alternative: ARNI (sacubitril/valsartan) can be initiated de novo without prior ACE-I exposure 1, 2

• Beta-blocker: Evidence-based agents (carvedilol, metoprolol succinate, or bisoprolol) 3

• Mineralocorticoid receptor antagonist: Spironolactone or eplerenone 3

• SGLT2 inhibitor: Dapagliflozin or empagliflozin—benefits are independent of diabetes status 1, 2

Practical Implementation Strategy

Initiation Timing

Begin all four medication classes simultaneously or within days of diagnosis 4, 5. The 2022 guidelines emphasize rapid initiation with target dose titration within 6-12 weeks 6. Studies demonstrate that starting at least 3 pillars at hospital discharge reduces all-cause mortality (HR 0.22), cardiovascular death (HR 0.21), and HF hospitalization (HR 0.28) 4.

Sequencing When Simultaneous Start Not Feasible

If you must sequence medications due to clinical concerns:

1. Start SGLT2i and beta-blocker first (shortest time-to-benefit, best tolerability profile)
2. Add ACE-I/ARNI within days
3. Add MRA once ACE-I/ARNI stabilized (typically within 1-2 weeks)

Mean time to quadruple therapy in real-world practice is 109 days 7, but this represents a gap in care—aim for completion within 4-6 weeks.

Addressing the "No Hypertension" Concern

The absence of hypertension is not a contraindication to any of these medications. 8 Multiple trials demonstrate that HF medications remain beneficial and safe even in normotensive patients, provided they are tolerated. The 2016 ESC guidelines explicitly state that ACE-I, beta-blockers, and MRAs reduce HF hospitalization and death in HFrEF regardless of blood pressure status 3.

Managing Hypotension Risk

• Start with low doses and monitor blood pressure
• If symptomatic hypotension occurs, reduce or temporarily hold diuretics first before reducing neurohormonal antagonists 9
• Prioritize maintaining GDMT over achieving arbitrary BP targets
• Evening dosing of ACE-I/ARNI may minimize orthostatic effects 10

Addressing the "No Diabetes" Concern

SGLT2 inhibitors provide mortality and hospitalization benefits in HFrEF patients without diabetes. 1, 2 The DAPA-HF and EMPEROR-Reduced trials demonstrated consistent benefits regardless of diabetes status 11. The 2022 guidelines give SGLT2i a Class I recommendation for all HFrEF patients, not just those with diabetes 1.

Monitoring and Titration

Initial Monitoring (First 1-2 Weeks)

• Blood pressure, heart rate
• Renal function (creatinine, eGFR)
• Electrolytes (potassium, sodium)

Dose Escalation Schedule

• Increase doses every 1-2 weeks as tolerated toward target doses used in landmark trials 10, 5
• Target doses matter: subtarget dosing without forced-titration strategies lacks evidence 12

Common Pitfalls to Avoid

1. Clinical inertia: Only 1-2% of HFrEF patients receive quadruple therapy in real-world practice 7—don't contribute to this gap
2. Premature discontinuation: 12-month discontinuation rates are high (51-62%) 7—anticipate and address tolerability issues proactively
3. Avoiding GDMT due to "borderline" BP or renal function: These medications are beneficial even with systolic BP 90-100 mmHg and eGFR >30 mL/min/1.73m² 9
4. Waiting to add SGLT2i: Mean time-to-initiation is 88 days in practice 7—this is too long

Special Considerations

If Patient Develops Hyperkalemia

• Check medication adherence and dietary potassium intake
• Consider potassium binders rather than stopping MRA 9
• MRA provides mortality benefit—preserve if possible

If Renal Function Deteriorates

• Small increases in creatinine (up to 30% or 0.3 mg/dL) are acceptable and expected 10
• Continue GDMT unless creatinine rises substantially or eGFR drops below 20-30 mL/min/1.73m²
• Renal impairment is the major factor limiting GDMT optimization, but studies show no increased risk of adverse renal outcomes with appropriate monitoring 4

Diuretics

• Use loop diuretics for congestion symptoms (Class I recommendation) 3
• Diuretics improve symptoms but don't reduce mortality—they're adjunctive to the four pillars
• Avoid NSAIDs and potassium-sparing diuretics during ACE-I/MRA initiation 10